Vardenafil
Description
Name: Vardenafil
Type: small molecule
Groups: approved
Indication: Used for the treatment of erectile dysfunction
Accession Number: DB00862 ( APRD00699)
Description: Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
Structure:
Prescription Products:
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: approved
Indication: Used for the treatment of erectile dysfunction
Accession Number: DB00862 ( APRD00699)
Description: Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Levitra | tablet, film coated | 20 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet | 5 mg | oral | 17-03-2004 | Canada | |
| Levitra | tablet | 10 mg | oral | 17-03-2004 | Canada | |
| Levitra | tablet | 20 mg | oral | 17-03-2004 | Canada | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 27-01-2004 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 05-03-2004 | US | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 28-10-2011 | US | |
| Levitra | tablet, film coated | 5 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 22-04-2011 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 22-04-2011 | US | |
| Levitra | tablet, film coated | 5 mg/1 | oral | 22-04-2011 | US | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 22-04-2011 | US | |
| Staxyn | tablet (orally disintegrating) | 10 mg | oral | 25-08-2011 | Canada | |
| Staxyn | tablet, orally disintegrating | 10 mg/1 | oral | 08-03-2012 | US |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Levitra | tablet, film coated | 20 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet | 5 mg | oral | 17-03-2004 | Canada | |
| Levitra | tablet | 10 mg | oral | 17-03-2004 | Canada | |
| Levitra | tablet | 20 mg | oral | 17-03-2004 | Canada | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 27-01-2004 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 05-03-2004 | US | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 28-10-2011 | US | |
| Levitra | tablet, film coated | 5 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 22-04-2011 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 15-05-2008 | US | |
| Levitra | tablet, film coated | 10 mg/1 | oral | 22-04-2011 | US | |
| Levitra | tablet, film coated | 5 mg/1 | oral | 22-04-2011 | US | |
| Levitra | tablet, film coated | 20 mg/1 | oral | 22-04-2011 | US | |
| Staxyn | tablet (orally disintegrating) | 10 mg | oral | 25-08-2011 | Canada | |
| Staxyn | tablet, orally disintegrating | 10 mg/1 | oral | 08-03-2012 | US |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Staxyn | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Staxyn | Vardenafil |
| Brand Name | Ingredients |
|---|---|
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Staxyn | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Levitra | Vardenafil |
| Staxyn | Vardenafil |
Categories
- Vasodilator Agents
- Phosphodiesterase 5 Inhibitors
- Anti-Impotence Agents
Pharmacology
Indication: Used for the treatment of erectile dysfunction
Pharmacodynamics: Not Available
Mechanism of action: Vardenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by vardenafil enhances erectile function by increasing the amount of cGMP.
Absorption: Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.
Volume of distribution:
Protein binding: 95%
Metabolism: Not Available
Route of elimination: After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose).
Half life: 4-5 hours
Clearance: Not Available
Toxicity: Symptoms of overdose include vision changes and back and muscle pain.
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: Vardenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by vardenafil enhances erectile function by increasing the amount of cGMP.
Absorption: Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.
Volume of distribution:
- 208 L
Protein binding: 95%
Metabolism: Not Available
Route of elimination: After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose).
Half life: 4-5 hours
Clearance: Not Available
Toxicity: Symptoms of overdose include vision changes and back and muscle pain.
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Bayer healthcare pharmaceuticals inc
Packagers:
- A-S Medication Solutions LLC
- Bayer Healthcare
- Bryant Ranch Prepack
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Murfreesboro Pharmaceutical Nursing Supply
- Physicians Total Care Inc.
- Prepak Systems Inc.
- Redpharm Drug
- Schering Corp.
- Va Cmop Dallas
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Tablet | oral | 10 mg |
| Tablet | oral | 20 mg |
| Tablet | oral | 5 mg |
| Tablet, film coated | oral | 10 mg/1 |
| Tablet, film coated | oral | 20 mg/1 |
| Tablet, film coated | oral | 5 mg/1 |
| Tablet (orally disintegrating) | oral | 10 mg |
| Tablet, orally disintegrating | oral | 10 mg/1 |
| Form | Route | Strength |
|---|---|---|
| Tablet | oral | 10 mg |
| Tablet | oral | 20 mg |
| Tablet | oral | 5 mg |
| Tablet, film coated | oral | 10 mg/1 |
| Tablet, film coated | oral | 20 mg/1 |
| Tablet, film coated | oral | 5 mg/1 |
| Tablet (orally disintegrating) | oral | 10 mg |
| Tablet, orally disintegrating | oral | 10 mg/1 |
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Levitra 2.5 mg tablet | $18.66 | tablet |
| Levitra 10 mg tablet | $19.04 | tablet |
| Levitra 20 mg tablet | $19.04 | tablet |
| Levitra 5 mg tablet | $19.04 | tablet |
| Unit description | Cost | Unit |
|---|---|---|
| Levitra 2.5 mg tablet | $18.66 | tablet |
| Levitra 10 mg tablet | $19.04 | tablet |
| Levitra 20 mg tablet | $19.04 | tablet |
| Levitra 5 mg tablet | $19.04 | tablet |
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|---|---|---|
| 2309332 | Canada | 2002-12-03 | 2018-10-31 |
| 6362178 | United States | 1998-10-31 | 2018-10-31 |
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|---|
| Acebutolol | Vardenafil may increase the antihypertensive activities of Acebutolol. |
| Alfuzosin | Vardenafil may increase the hypotensive activities of Alfuzosin. |
| Aliskiren | Vardenafil may increase the antihypertensive activities of Aliskiren. |
| Alprostadil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Alprostadil. |
| Amiloride | Vardenafil may increase the antihypertensive activities of Amiloride. |
| Amlodipine | Vardenafil may increase the antihypertensive activities of Amlodipine. |
| Amyl Nitrite | Vardenafil may increase the vasodilatory activities of Amyl Nitrite. |
| Aprepitant | The serum concentration of Vardenafil can be increased when it is combined with Aprepitant. |
| Atazanavir | The serum concentration of Vardenafil can be increased when it is combined with Atazanavir. |
| Atenolol | Vardenafil may increase the antihypertensive activities of Atenolol. |
| Avanafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Avanafil. |
| Azilsartan medoxomil | Vardenafil may increase the antihypertensive activities of Azilsartan medoxomil. |
| Benazepril | Vardenafil may increase the antihypertensive activities of Benazepril. |
| Bendroflumethiazide | Vardenafil may increase the antihypertensive activities of Bendroflumethiazide. |
| Betaxolol | Vardenafil may increase the antihypertensive activities of Betaxolol. |
| Bisoprolol | Vardenafil may increase the antihypertensive activities of Bisoprolol. |
| Boceprevir | The serum concentration of Vardenafil can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Vardenafil can be decreased when it is combined with Bosentan. |
| Bumetanide | Vardenafil may increase the antihypertensive activities of Bumetanide. |
| Candesartan | Vardenafil may increase the antihypertensive activities of Candesartan. |
| Captopril | Vardenafil may increase the antihypertensive activities of Captopril. |
| Carvedilol | Vardenafil may increase the antihypertensive activities of Carvedilol. |
| Ceritinib | The serum concentration of Vardenafil can be increased when it is combined with Ceritinib. |
| Chlorothiazide | Vardenafil may increase the antihypertensive activities of Chlorothiazide. |
| Chlorthalidone | Vardenafil may increase the antihypertensive activities of Chlorthalidone. |
| Cilazapril | Vardenafil may increase the antihypertensive activities of Cilazapril. |
| Citalopram | Vardenafil may increase the QTc-prolonging activities of Citalopram. |
| Clarithromycin | The serum concentration of Vardenafil can be increased when it is combined with Clarithromycin. |
| Clevidipine | Vardenafil may increase the antihypertensive activities of Clevidipine. |
| Clonidine | Vardenafil may increase the antihypertensive activities of Clonidine. |
| Cobicistat | The serum concentration of Vardenafil can be increased when it is combined with Cobicistat. |
| Conivaptan | The serum concentration of Vardenafil can be increased when it is combined with Conivaptan. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Vardenafil. |
| Darunavir | The serum concentration of Vardenafil can be increased when it is combined with Darunavir. |
| Dasatinib | The serum concentration of Vardenafil can be increased when it is combined with Dasatinib. |
| Diltiazem | Vardenafil may increase the antihypertensive activities of Diltiazem. |
| Dofetilide | Vardenafil may increase the QTc-prolonging activities of Dofetilide. |
| Doxazosin | Vardenafil may increase the hypotensive activities of Doxazosin. |
| Enalapril | Vardenafil may increase the antihypertensive activities of Enalapril. |
| Enalaprilat | Vardenafil may increase the antihypertensive activities of Enalaprilat. |
| Eplerenone | Vardenafil may increase the antihypertensive activities of Eplerenone. |
| Eprosartan | Vardenafil may increase the antihypertensive activities of Eprosartan. |
| Erythrityl Tetranitrate | Vardenafil may increase the vasodilatory activities of Erythrityl Tetranitrate. |
| Erythromycin | The serum concentration of Vardenafil can be increased when it is combined with Erythromycin. |
| Esmolol | Vardenafil may increase the antihypertensive activities of Esmolol. |
| Ethacrynic acid | Vardenafil may increase the antihypertensive activities of Ethacrynic acid. |
| Ethanol | Ethanol may increase the hypotensive activities of Vardenafil. |
| Etravirine | The serum concentration of Vardenafil can be decreased when it is combined with Etravirine. |
| Felodipine | Vardenafil may increase the antihypertensive activities of Felodipine. |
| Fluconazole | The metabolism of Vardenafil can be decreased when combined with Fluconazole. |
| Fosaprepitant | The serum concentration of Vardenafil can be increased when it is combined with Fosaprepitant. |
| Fosinopril | Vardenafil may increase the antihypertensive activities of Fosinopril. |
| Furosemide | Vardenafil may increase the antihypertensive activities of Furosemide. |
| Fusidic Acid | The serum concentration of Vardenafil can be increased when it is combined with Fusidic Acid. |
| Goserelin | Vardenafil may increase the QTc-prolonging activities of Goserelin. |
| Guanfacine | Vardenafil may increase the antihypertensive activities of Guanfacine. |
| Hydralazine | Vardenafil may increase the antihypertensive activities of Hydralazine. |
| Hydrochlorothiazide | Vardenafil may increase the antihypertensive activities of Hydrochlorothiazide. |
| Idelalisib | The serum concentration of Vardenafil can be increased when it is combined with Idelalisib. |
| Indapamide | Vardenafil may increase the antihypertensive activities of Indapamide. |
| Indinavir | The serum concentration of Vardenafil can be increased when it is combined with Indinavir. |
| Irbesartan | Vardenafil may increase the antihypertensive activities of Irbesartan. |
| Isosorbide | Vardenafil may increase the vasodilatory activities of Isosorbide. |
| Isosorbide Dinitrate | Vardenafil may increase the vasodilatory activities of Isosorbide Dinitrate. |
| Isosorbide Mononitrate | Vardenafil may increase the vasodilatory activities of Isosorbide Mononitrate. |
| Isradipine | Vardenafil may increase the antihypertensive activities of Isradipine. |
| Itraconazole | The serum concentration of Vardenafil can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Vardenafil can be increased when it is combined with Ivacaftor. |
| Ketoconazole | The serum concentration of Vardenafil can be increased when it is combined with Ketoconazole. |
| Labetalol | Vardenafil may increase the antihypertensive activities of Labetalol. |
| Leuprolide | Vardenafil may increase the QTc-prolonging activities of Leuprolide. |
| Lisinopril | Vardenafil may increase the antihypertensive activities of Lisinopril. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Vardenafil. |
| Losartan | Vardenafil may increase the antihypertensive activities of Losartan. |
| Luliconazole | The serum concentration of Vardenafil can be increased when it is combined with Luliconazole. |
| Mannitol | Vardenafil may increase the antihypertensive activities of Mannitol. |
| Mecamylamine | Vardenafil may increase the antihypertensive activities of Mecamylamine. |
| Methyclothiazide | Vardenafil may increase the antihypertensive activities of Methyclothiazide. |
| Methyldopa | Vardenafil may increase the antihypertensive activities of Methyldopa. |
| Metolazone | Vardenafil may increase the antihypertensive activities of Metolazone. |
| Metoprolol | Vardenafil may increase the antihypertensive activities of Metoprolol. |
| Mifepristone | The serum concentration of Vardenafil can be increased when it is combined with Mifepristone. |
| Minoxidil | Vardenafil may increase the antihypertensive activities of Minoxidil. |
| Moexipril | Vardenafil may increase the antihypertensive activities of Moexipril. |
| Molsidomine | Molsidomine may increase the hypotensive activities of Vardenafil. |
| Moxonidine | Vardenafil may increase the antihypertensive activities of Moxonidine. |
| Nadolol | Vardenafil may increase the antihypertensive activities of Nadolol. |
| Nebivolol | Vardenafil may increase the antihypertensive activities of Nebivolol. |
| Nefazodone | The serum concentration of Vardenafil can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Vardenafil can be increased when it is combined with Nelfinavir. |
| Netupitant | The serum concentration of Vardenafil can be increased when it is combined with Netupitant. |
| Nicardipine | Vardenafil may increase the antihypertensive activities of Nicardipine. |
| Nifedipine | Vardenafil may increase the antihypertensive activities of Nifedipine. |
| Nimodipine | Vardenafil may increase the antihypertensive activities of Nimodipine. |
| Nisoldipine | Vardenafil may increase the antihypertensive activities of Nisoldipine. |
| Nitroglycerin | Vardenafil may increase the vasodilatory activities of Nitroglycerin. |
| Nitroprusside | Vardenafil may increase the antihypertensive activities of Nitroprusside. |
| Olmesartan | Vardenafil may increase the antihypertensive activities of Olmesartan. |
| Palbociclib | The serum concentration of Vardenafil can be increased when it is combined with Palbociclib. |
| Penbutolol | Vardenafil may increase the antihypertensive activities of Penbutolol. |
| Perindopril | Vardenafil may increase the antihypertensive activities of Perindopril. |
| Phenoxybenzamine | Vardenafil may increase the hypotensive activities of Phenoxybenzamine. |
| Phentolamine | Vardenafil may increase the hypotensive activities of Phentolamine. |
| Pindolol | Vardenafil may increase the antihypertensive activities of Pindolol. |
| Posaconazole | The serum concentration of Vardenafil can be increased when it is combined with Posaconazole. |
| Prazosin | Vardenafil may increase the hypotensive activities of Prazosin. |
| Propranolol | Vardenafil may increase the antihypertensive activities of Propranolol. |
| Quinapril | Vardenafil may increase the antihypertensive activities of Quinapril. |
| Ramipril | Vardenafil may increase the antihypertensive activities of Ramipril. |
| Reserpine | Vardenafil may increase the antihypertensive activities of Reserpine. |
| Riociguat | Vardenafil may increase the hypotensive activities of Riociguat. |
| Ritonavir | The serum concentration of Vardenafil can be increased when it is combined with Ritonavir. |
| Saquinavir | The serum concentration of Vardenafil can be increased when it is combined with Saquinavir. |
| Sildenafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Sildenafil. |
| Silodosin | Vardenafil may increase the hypotensive activities of Silodosin. |
| Simeprevir | The serum concentration of Vardenafil can be increased when it is combined with Simeprevir. |
| Sotalol | Vardenafil may increase the antihypertensive activities of Sotalol. |
| Spironolactone | Vardenafil may increase the antihypertensive activities of Spironolactone. |
| Stiripentol | The serum concentration of Vardenafil can be increased when it is combined with Stiripentol. |
| Tadalafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Tadalafil. |
| Tamsulosin | Vardenafil may increase the hypotensive activities of Tamsulosin. |
| Telaprevir | The serum concentration of Vardenafil can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Vardenafil can be increased when it is combined with Telithromycin. |
| Telmisartan | Vardenafil may increase the antihypertensive activities of Telmisartan. |
| Terazosin | Vardenafil may increase the hypotensive activities of Terazosin. |
| Tetrahydrobiopterin | Tetrahydrobiopterin may increase the hypotensive activities of Vardenafil. |
| Timolol | Vardenafil may increase the antihypertensive activities of Timolol. |
| Torasemide | Vardenafil may increase the antihypertensive activities of Torasemide. |
| Trandolapril | Vardenafil may increase the antihypertensive activities of Trandolapril. |
| Triamterene | Vardenafil may increase the antihypertensive activities of Triamterene. |
| Valsartan | Vardenafil may increase the antihypertensive activities of Valsartan. |
| Verapamil | Vardenafil may increase the antihypertensive activities of Verapamil. |
| Voriconazole | The serum concentration of Vardenafil can be increased when it is combined with Voriconazole. |
| Drug | Interaction |
|---|---|
| Acebutolol | Vardenafil may increase the antihypertensive activities of Acebutolol. |
| Alfuzosin | Vardenafil may increase the hypotensive activities of Alfuzosin. |
| Aliskiren | Vardenafil may increase the antihypertensive activities of Aliskiren. |
| Alprostadil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Alprostadil. |
| Amiloride | Vardenafil may increase the antihypertensive activities of Amiloride. |
| Amlodipine | Vardenafil may increase the antihypertensive activities of Amlodipine. |
| Amyl Nitrite | Vardenafil may increase the vasodilatory activities of Amyl Nitrite. |
| Aprepitant | The serum concentration of Vardenafil can be increased when it is combined with Aprepitant. |
| Atazanavir | The serum concentration of Vardenafil can be increased when it is combined with Atazanavir. |
| Atenolol | Vardenafil may increase the antihypertensive activities of Atenolol. |
| Avanafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Avanafil. |
| Azilsartan medoxomil | Vardenafil may increase the antihypertensive activities of Azilsartan medoxomil. |
| Benazepril | Vardenafil may increase the antihypertensive activities of Benazepril. |
| Bendroflumethiazide | Vardenafil may increase the antihypertensive activities of Bendroflumethiazide. |
| Betaxolol | Vardenafil may increase the antihypertensive activities of Betaxolol. |
| Bisoprolol | Vardenafil may increase the antihypertensive activities of Bisoprolol. |
| Boceprevir | The serum concentration of Vardenafil can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Vardenafil can be decreased when it is combined with Bosentan. |
| Bumetanide | Vardenafil may increase the antihypertensive activities of Bumetanide. |
| Candesartan | Vardenafil may increase the antihypertensive activities of Candesartan. |
| Captopril | Vardenafil may increase the antihypertensive activities of Captopril. |
| Carvedilol | Vardenafil may increase the antihypertensive activities of Carvedilol. |
| Ceritinib | The serum concentration of Vardenafil can be increased when it is combined with Ceritinib. |
| Chlorothiazide | Vardenafil may increase the antihypertensive activities of Chlorothiazide. |
| Chlorthalidone | Vardenafil may increase the antihypertensive activities of Chlorthalidone. |
| Cilazapril | Vardenafil may increase the antihypertensive activities of Cilazapril. |
| Citalopram | Vardenafil may increase the QTc-prolonging activities of Citalopram. |
| Clarithromycin | The serum concentration of Vardenafil can be increased when it is combined with Clarithromycin. |
| Clevidipine | Vardenafil may increase the antihypertensive activities of Clevidipine. |
| Clonidine | Vardenafil may increase the antihypertensive activities of Clonidine. |
| Cobicistat | The serum concentration of Vardenafil can be increased when it is combined with Cobicistat. |
| Conivaptan | The serum concentration of Vardenafil can be increased when it is combined with Conivaptan. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Vardenafil. |
| Darunavir | The serum concentration of Vardenafil can be increased when it is combined with Darunavir. |
| Dasatinib | The serum concentration of Vardenafil can be increased when it is combined with Dasatinib. |
| Diltiazem | Vardenafil may increase the antihypertensive activities of Diltiazem. |
| Dofetilide | Vardenafil may increase the QTc-prolonging activities of Dofetilide. |
| Doxazosin | Vardenafil may increase the hypotensive activities of Doxazosin. |
| Enalapril | Vardenafil may increase the antihypertensive activities of Enalapril. |
| Enalaprilat | Vardenafil may increase the antihypertensive activities of Enalaprilat. |
| Eplerenone | Vardenafil may increase the antihypertensive activities of Eplerenone. |
| Eprosartan | Vardenafil may increase the antihypertensive activities of Eprosartan. |
| Erythrityl Tetranitrate | Vardenafil may increase the vasodilatory activities of Erythrityl Tetranitrate. |
| Erythromycin | The serum concentration of Vardenafil can be increased when it is combined with Erythromycin. |
| Esmolol | Vardenafil may increase the antihypertensive activities of Esmolol. |
| Ethacrynic acid | Vardenafil may increase the antihypertensive activities of Ethacrynic acid. |
| Ethanol | Ethanol may increase the hypotensive activities of Vardenafil. |
| Etravirine | The serum concentration of Vardenafil can be decreased when it is combined with Etravirine. |
| Felodipine | Vardenafil may increase the antihypertensive activities of Felodipine. |
| Fluconazole | The metabolism of Vardenafil can be decreased when combined with Fluconazole. |
| Fosaprepitant | The serum concentration of Vardenafil can be increased when it is combined with Fosaprepitant. |
| Fosinopril | Vardenafil may increase the antihypertensive activities of Fosinopril. |
| Furosemide | Vardenafil may increase the antihypertensive activities of Furosemide. |
| Fusidic Acid | The serum concentration of Vardenafil can be increased when it is combined with Fusidic Acid. |
| Goserelin | Vardenafil may increase the QTc-prolonging activities of Goserelin. |
| Guanfacine | Vardenafil may increase the antihypertensive activities of Guanfacine. |
| Hydralazine | Vardenafil may increase the antihypertensive activities of Hydralazine. |
| Hydrochlorothiazide | Vardenafil may increase the antihypertensive activities of Hydrochlorothiazide. |
| Idelalisib | The serum concentration of Vardenafil can be increased when it is combined with Idelalisib. |
| Indapamide | Vardenafil may increase the antihypertensive activities of Indapamide. |
| Indinavir | The serum concentration of Vardenafil can be increased when it is combined with Indinavir. |
| Irbesartan | Vardenafil may increase the antihypertensive activities of Irbesartan. |
| Isosorbide | Vardenafil may increase the vasodilatory activities of Isosorbide. |
| Isosorbide Dinitrate | Vardenafil may increase the vasodilatory activities of Isosorbide Dinitrate. |
| Isosorbide Mononitrate | Vardenafil may increase the vasodilatory activities of Isosorbide Mononitrate. |
| Isradipine | Vardenafil may increase the antihypertensive activities of Isradipine. |
| Itraconazole | The serum concentration of Vardenafil can be increased when it is combined with Itraconazole. |
| Ivacaftor | The serum concentration of Vardenafil can be increased when it is combined with Ivacaftor. |
| Ketoconazole | The serum concentration of Vardenafil can be increased when it is combined with Ketoconazole. |
| Labetalol | Vardenafil may increase the antihypertensive activities of Labetalol. |
| Leuprolide | Vardenafil may increase the QTc-prolonging activities of Leuprolide. |
| Lisinopril | Vardenafil may increase the antihypertensive activities of Lisinopril. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Vardenafil. |
| Losartan | Vardenafil may increase the antihypertensive activities of Losartan. |
| Luliconazole | The serum concentration of Vardenafil can be increased when it is combined with Luliconazole. |
| Mannitol | Vardenafil may increase the antihypertensive activities of Mannitol. |
| Mecamylamine | Vardenafil may increase the antihypertensive activities of Mecamylamine. |
| Methyclothiazide | Vardenafil may increase the antihypertensive activities of Methyclothiazide. |
| Methyldopa | Vardenafil may increase the antihypertensive activities of Methyldopa. |
| Metolazone | Vardenafil may increase the antihypertensive activities of Metolazone. |
| Metoprolol | Vardenafil may increase the antihypertensive activities of Metoprolol. |
| Mifepristone | The serum concentration of Vardenafil can be increased when it is combined with Mifepristone. |
| Minoxidil | Vardenafil may increase the antihypertensive activities of Minoxidil. |
| Moexipril | Vardenafil may increase the antihypertensive activities of Moexipril. |
| Molsidomine | Molsidomine may increase the hypotensive activities of Vardenafil. |
| Moxonidine | Vardenafil may increase the antihypertensive activities of Moxonidine. |
| Nadolol | Vardenafil may increase the antihypertensive activities of Nadolol. |
| Nebivolol | Vardenafil may increase the antihypertensive activities of Nebivolol. |
| Nefazodone | The serum concentration of Vardenafil can be increased when it is combined with Nefazodone. |
| Nelfinavir | The serum concentration of Vardenafil can be increased when it is combined with Nelfinavir. |
| Netupitant | The serum concentration of Vardenafil can be increased when it is combined with Netupitant. |
| Nicardipine | Vardenafil may increase the antihypertensive activities of Nicardipine. |
| Nifedipine | Vardenafil may increase the antihypertensive activities of Nifedipine. |
| Nimodipine | Vardenafil may increase the antihypertensive activities of Nimodipine. |
| Nisoldipine | Vardenafil may increase the antihypertensive activities of Nisoldipine. |
| Nitroglycerin | Vardenafil may increase the vasodilatory activities of Nitroglycerin. |
| Nitroprusside | Vardenafil may increase the antihypertensive activities of Nitroprusside. |
| Olmesartan | Vardenafil may increase the antihypertensive activities of Olmesartan. |
| Palbociclib | The serum concentration of Vardenafil can be increased when it is combined with Palbociclib. |
| Penbutolol | Vardenafil may increase the antihypertensive activities of Penbutolol. |
| Perindopril | Vardenafil may increase the antihypertensive activities of Perindopril. |
| Phenoxybenzamine | Vardenafil may increase the hypotensive activities of Phenoxybenzamine. |
| Phentolamine | Vardenafil may increase the hypotensive activities of Phentolamine. |
| Pindolol | Vardenafil may increase the antihypertensive activities of Pindolol. |
| Posaconazole | The serum concentration of Vardenafil can be increased when it is combined with Posaconazole. |
| Prazosin | Vardenafil may increase the hypotensive activities of Prazosin. |
| Propranolol | Vardenafil may increase the antihypertensive activities of Propranolol. |
| Quinapril | Vardenafil may increase the antihypertensive activities of Quinapril. |
| Ramipril | Vardenafil may increase the antihypertensive activities of Ramipril. |
| Reserpine | Vardenafil may increase the antihypertensive activities of Reserpine. |
| Riociguat | Vardenafil may increase the hypotensive activities of Riociguat. |
| Ritonavir | The serum concentration of Vardenafil can be increased when it is combined with Ritonavir. |
| Saquinavir | The serum concentration of Vardenafil can be increased when it is combined with Saquinavir. |
| Sildenafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Sildenafil. |
| Silodosin | Vardenafil may increase the hypotensive activities of Silodosin. |
| Simeprevir | The serum concentration of Vardenafil can be increased when it is combined with Simeprevir. |
| Sotalol | Vardenafil may increase the antihypertensive activities of Sotalol. |
| Spironolactone | Vardenafil may increase the antihypertensive activities of Spironolactone. |
| Stiripentol | The serum concentration of Vardenafil can be increased when it is combined with Stiripentol. |
| Tadalafil | The risk or severity of adverse effects can be increased when Vardenafil is combined with Tadalafil. |
| Tamsulosin | Vardenafil may increase the hypotensive activities of Tamsulosin. |
| Telaprevir | The serum concentration of Vardenafil can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Vardenafil can be increased when it is combined with Telithromycin. |
| Telmisartan | Vardenafil may increase the antihypertensive activities of Telmisartan. |
| Terazosin | Vardenafil may increase the hypotensive activities of Terazosin. |
| Tetrahydrobiopterin | Tetrahydrobiopterin may increase the hypotensive activities of Vardenafil. |
| Timolol | Vardenafil may increase the antihypertensive activities of Timolol. |
| Torasemide | Vardenafil may increase the antihypertensive activities of Torasemide. |
| Trandolapril | Vardenafil may increase the antihypertensive activities of Trandolapril. |
| Triamterene | Vardenafil may increase the antihypertensive activities of Triamterene. |
| Valsartan | Vardenafil may increase the antihypertensive activities of Valsartan. |
| Verapamil | Vardenafil may increase the antihypertensive activities of Verapamil. |
| Voriconazole | The serum concentration of Vardenafil can be increased when it is combined with Voriconazole. |
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- 1,2,4-triazines
- Alkyl aryl ethers
- Azacyclic compounds
- Heteroaromatic compounds
- Hydrocarbon derivatives
- N-alkylpiperazines
- N-substituted imidazoles
- Phenol ethers
- Sulfonamides
- Sulfonyls
- Trialkylamines
substituent:
- 1,2,4-triazine
- 1,4-diazinane
- Alkyl aryl ether
- Amine
- Aromatic heteropolycyclic compound
- Azacycle
- Azole
- Benzenesulfonamide
- Ether
- Heteroaromatic compound
- Hydrocarbon derivative
- Imidazole
- N-alkylpiperazine
- N-substituted imidazole
- Organoheterocyclic compound
- Organonitrogen compound
- Organooxygen compound
- Organosulfur compound
- Phenol ether
- Piperazine
- Sulfonamide
- Sulfonic acid derivative
- Sulfonyl
- Tertiary aliphatic amine
- Tertiary amine
- Triazine
References
Synthesis Reference: Yogesh S. Deshpande, Sandra Brueck, Julia Schulze Nahrup, Birgit Schnitter, Ganesh Gat, Javed Hussain, "PROCESS FOR THE PREPARATION OF A MEDICAMENT COMPRISING VARDENAFIL HYDROCHLORIDE TRIHYDRATE." U.S. Patent US20100159003, issued June 24, 2010.
General Reference: Not Available
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: Not Available
External Links:
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic3/levitra.htm |
| PDRhealth | http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/lev1688.shtml |
| Drugs.com | http://www.drugs.com/cdi/vardenafil.html |
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic3/levitra.htm |
| PDRhealth | http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/lev1688.shtml |
| Drugs.com | http://www.drugs.com/cdi/vardenafil.html |
ATC Codes:
- Array
AHFS Codes:
- 24:12.12
MSDS: Download